What is SEPN's P/E ratio?

Septerna, Inc. Common Stock (SEPN) currently trades at a P/E ratio of 192.92.

Septerna, Inc. Common Stock reports a Return on Equity (ROE) of -9.52%.

What is SEPN's dividend yield?

Septerna, Inc. Common Stock offers a dividend yield of 0.00%.

What is SEPN's Quality Score?

Our AI rates SEPN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SEPN?

Our AI Timing Score for SEPN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SEPN belong to?

Septerna, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Septerna, Inc. (SEPN) Stock Price, Quality Score & AI Analysis

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

SEPN AI Analysis Summary

Our AI summary for SEPN: Septerna, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 192.92, ROE of -9.52%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SEPN

Septerna, Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 38.98

4.00 (11.44%) Day Change

Watchlist Portfolio Compare Chart

192.92

P/E

0.01

D/E

-9.5%

ROE

-6.3%

ROA

0.00%

Div Yield

-0.50

PEG

SEPTERNA, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 38.98 Price 4.00 (11.44%) Day Change	NEWS SCORE: 97

SEPN, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	38.98
PBV / Sector	4.17 / 44,022.72
Earning Per Share	-0.89

PE / Sector	192.92 / 19.17
PEG or PE/Growth / Sector	-0.50 / 1.24
Average 1M Daily Value	12.44 M GREAT
Average 1W Daily Value	8.87 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-49.88 / 98.24
NPM Average (%) / Sector	-1,016.73 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-6.33 / 185,260.96
ROA Average (%) / Sector	-20.74 / 36,684.70
ROA Change Average (%) / Sector	-191.81 / 422,221.66
ROE (%) / Sector	-9.52 / 243,762.23
ROE Average (%) / Sector	2.46 / 48,758.47
ROE Change Average (%) / Sector	-27.80 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:50
Symbol	SEPN
Name	SEPTERNA, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	45.08 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,576.74 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 250 East Grand Avenue, South San Francisco, CA, United States, 94080

Phone: 650 338 3533

Website: https://septerna.com

Employees: 130

Sector: Healthcare >> Biotechnology

Description: Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.